Skip to main content
OpenTrials
Completed

NCT Number: NCT01209364

Durolane Versus Methylprednisolone in Knee Osteoarthritis

The primary objective is to determine whether Durolane is non-inferior to methylprednisolone, as assessed by level of pain, when each are given as single intra-articular injections for the relief of pain, in the treatment of symptomatic osteoarthritis of the knee at 12 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Alberta Bone & Joint Health Institute, Calgary, Alberta, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject (female or male) 35-80 years of age
  • Unilateral knee pain
  • Radiographic evidence of OA
  • WOMAC pain score of 7-17
  • Subject normally active
  • Subject has attempted but not responded adequately to previous non-pharmacological therapy(ies);
  • Subject cooperative and able to communicate effectively with the investigators;
  • Body mass index ≤ 40 kg/m2;
  • Signed informed consent obtained.

Exclusion criteria

  • Knee effusion
  • Contralateral knee OA
  • Clinically significant joint pain from joints other than the knee
  • Previous intra-articular steroid injection into the study knee within the last 3 months;
  • Previous intra-articular HA injection into the study knee within the last 9 months;
  • Previous allergic type reaction to a HA product, a steroid, or lidocaine/related anesthetics;
  • Treatment with analgesics other than paracetamol (acetaminophen) (including topical agents for the knee) within 5 half lives of the drug prior to the baseline visit;
  • Use of systemic glucocorticosteroids (excluding inhaled steroids) within the last 3 months;
  • Treatment with glucosamine/chondroitin sulfate initiated within the past 3 months
  • Change in physical therapy for the knee within the last three months
  • Arthroscopy or other surgical procedure in the study knee within the past 12 months;
  • Any planned arthroscopy or other surgical procedure during the study period;
  • Previous history or presence of active septic arthritis
  • Active skin disease or infection in the area of the injection site;
  • Systemic active inflammatory condition or infection
  • Bleeding diathesis or use of anticoagulants
  • Current uncontrolled diabetes mellitus;
  • Any medical condition that in the opinion of the investigator makes the subject unsuitable for inclusion
  • Pregnant or breastfeeding woman or woman of childbearing potential not practicing adequate contraception;
  • Involvement in other clinical trials

Treatment and study plan

Durolane is a device, methylprednisolone in a drug

Device

single intraarticular injection

Other names: Durolane and Depo-Medrol are the brand names

Primary outcomes

  1. Pain level and responder rate

    Time frame: up to 12 weeks

Secondary outcomes

  1. WOMAC stiffness score

    Time frame: 26 weeks blinded phase + 26 weeks OLE

    Will be assessed at each clinic visit

  2. WOMAC physical function

    Time frame: 26 weeks blinded phase + 26 weeks OLE

    Will be assessed at each clinic visit

  3. Functional assessment

    Time frame: 26 weeks blinded phase + 26 weeks OLE

    Will be assessed at each clinic visit

  4. Safety assessment (Adverse Events)

    Time frame: 26 weeks blinded phase + 26 weeks OLE

    Will be assessed at each clinic visit using standard questions

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Registry information

Official study title

Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects With Osteoarthritis of the Knee

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Sep 27, 2010
Registry last updated
Aug 25, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.